Vedana Lands $46M to Develop Anti-PACAP Peptide Therapies for Migraine

Executive Summary

Vedana Therapeutics launched from stealth on June 17, 2026, with $46 million in funding to develop anti-PACAP peptide therapies for migraine prevention. The biotech targets the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway — a peptide signaling axis that has emerged as the next major frontier in migraine drug development after the commercial success of CGRP inhibitors. With more than half of migraine patients failing or discontinuing CGRP-targeted therapies, the anti-PACAP approach represents one of the most significant peptide therapeutic opportunities in neurology.

Context / Background

The migraine therapeutic landscape was transformed in 2018–2020 by the arrival of CGRP (calcitonin gene-related peptide) inhibitors — monoclonal antibodies and small-molecule antagonists from Amgen, Eli Lilly, Teva, and Lundbeck that collectively built a multibillion-dollar market. These drugs target a 37-amino-acid neuropeptide central to migraine pathophysiology. However, real-world data has since revealed a ceiling effect: an estimated 40–60% of patients either do not respond adequately to CGRP blockade or discontinue treatment due to side effects or waning efficacy.

PACAP (pituitary adenylate cyclase-activating polypeptide) is a 38-amino-acid peptide in the same secretin/glucagon superfamily as CGRP. Both peptides are released from trigeminal nerve terminals during migraine attacks and activate overlapping but distinct signaling cascades. The key insight driving Vedana’s thesis: PACAP triggers migraine through pathways independent of CGRP, meaning patients who fail CGRP therapies may still benefit from PACAP blockade.

The Data / The Deal

Expert Insight

Anti-pattern the market is missing: Most analysis frames PACAP as “the next CGRP” — a straightforward second target in a linear progression. The reality is more nuanced. PACAP signals through three distinct receptors (PAC1, VPAC1, VPAC2), each with different tissue distributions and functional roles. Unlike CGRP, where blocking one receptor (CGRP-R) or one ligand suffices, anti-PACAP drug developers face a receptor selectivity problem: PAC1 blockade in the trigeminovascular system may prevent migraine, but VPAC1/VPAC2 are broadly expressed in the cardiovascular, gastrointestinal, and immune systems. Non-selective PACAP blockade risks systemic side effects that CGRP inhibitors largely avoid.

A second underappreciated factor: PACAP and CGRP are co-released and may functionally compensate for each other. Blocking one pathway could upregulate the other, meaning the real clinical opportunity may be combination therapy (CGRP + PACAP dual blockade), not replacement monotherapy. Vedana’s peptide-based approach could enable more flexible combination strategies compared to antibody platforms.

Frequently Asked Questions

What is PACAP and why is it important in migraine?

PACAP (pituitary adenylate cyclase-activating polypeptide) is a 38-amino-acid neuropeptide released from trigeminal nerve endings during migraine attacks. It activates PAC1, VPAC1, and VPAC2 receptors to promote vasodilation, neurogenic inflammation, and pain transmission. Crucially, PACAP triggers migraine through pathways independent of CGRP, making it an attractive target for the 40–60% of patients who do not respond to existing CGRP-inhibitor therapies.

How does the anti-PACAP approach differ from CGRP inhibitors?

CGRP inhibitors block calcitonin gene-related peptide or its receptor and have been the dominant migraine prevention strategy since 2018. Anti-PACAP therapies target a different neuropeptide that acts through parallel signaling pathways. The key advantage: patients who fail CGRP drugs may still respond to PACAP blockade. The two approaches may eventually be complementary, with dual CGRP/PACAP blockade potentially offering additive or synergistic efficacy.

What does Vedana’s $46M funding signal about the peptide therapeutics market?

The $46M Series A reflects growing investor conviction that peptide-based approaches to neurology represent a major untapped opportunity. The anti-PACAP field has attracted attention from both large pharma (Lundbeck, Amgen) and now venture-backed startups. More broadly, the deal underscores a structural shift: after two decades of small-molecule dominance in neurology, peptide and biologic modalities are capturing an increasing share of CNS drug development funding. The migraine market alone — valued at approximately $7 billion annually — provides sufficient commercial incentive for multiple competing mechanisms.

Further Reading

• GLP-1 Receptor Agonists and Lean Body Mass: What 36 Trials Reveal
• Peptide Therapeutics Pipeline Review 2026
• The CGRP Inhibitor Market at Maturity: Lessons for Anti-PACAP Developers

Last reviewed: June 2026. Peptide Proof Editorial Team. Source: BioPharma Dive, June 17, 2026.